Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.
OBJECTIVE
Diagnosis of triple-negative breast cancer (TNBC) is associated with adverse prognosis, particularly in cases of chemotherapy resistance. The goal of this analysis was to compare TNBC vs. non-TNBC cell lines and those of distinct TNBC subtypes with regard to sensitivity to eribulin in vitro.


METHODS
Breast cancer cell lines were subjected to cell-viability assays, apoptosis analyses, migration and invasion experiments, and quantitative real-time polymerase chain reaction after exposure to eribulin.


RESULTS
Eribulin reduced cell viability in TNBC and non-TNBC cell lines in the sub-nanomolar range. Furthermore, exposure to eribulin induced apoptosis and decreased the rate of migration and invasion. Genes known to induce malignant transformation were differentially expressed after eribulin treatment.


CONCLUSIONS
Eribulin had a strong antiproliferative effect on breast cancer cell lines, although we did not observe a significant difference between TNBC and non-TNBC cell lines with regard to sensitivity to eribulin.
Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany Karen.Braeutigam@uksh.de.
Karen
K
Bräutigam
Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Katharina
K
Mitzlaff
Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Lisa
L
Uebel
Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Frank
F
Köster
Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Stephan
S
Polack
Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Mascha
M
Pervan
Eisai GmbH, Frankfurt am Main, Germany.
Gunnar
G
Steinert
Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Achim
A
Rody
Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Cornelia
C
Liedtke
D050256:Antimitotic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D005260:Female; D005663:Furans / Q000494:pharmacology*; D006801:Humans; D007659:Ketones / Q000494:pharmacology*; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000095662:Polyether Polyketides
D050256:Antimitotic Agents; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides
TNBC; Triple-negative breast cancer; apoptosis; cell lines; chemosensitivity; eribulin; gene expression; invasion; malignant transformation; migration; proliferation; subtypes